Skip to main navigation Skip to search Skip to main content

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

  • Charu Aggarwal
  • , Jeffrey C. Thompson
  • , Austin L. Chien
  • , Katie J. Quinn
  • , Wei Ting Hwang
  • , Taylor A. Black
  • , Stephanie S. Yee
  • , Theresa E. Christensen
  • , Michael J. LaRiviere
  • , Benjamin A. Silva
  • , Kimberly C. Banks
  • , Rebecca J. Nagy
  • , Elena Helman
  • , Abigail T. Berman
  • , Christine A. Ciunci
  • , Aditi P. Singh
  • , Jeffrey S. Wasser
  • , Joshua M. Bauml
  • , Corey J. Langer
  • , Roger B. Cohen
  • Erica L. Carpenter
  • University of Pennsylvania
  • Guardant Health Inc
  • University of Connecticut

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Fingerprint

Dive into the research topics of 'Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry